Assessment of angle closure disease in the age of artificial intelligence: A review.

Journal: Progress in retinal and eye research
PMID:

Abstract

Primary angle closure glaucoma is a visually debilitating disease that is under-detected worldwide. Many of the challenges in managing primary angle closure disease (PACD) are related to the lack of convenient and precise tools for clinic-based disease assessment and monitoring. Artificial intelligence (AI)- assisted tools to detect and assess PACD have proliferated in recent years with encouraging results. Machine learning (ML) algorithms that utilize clinical data have been developed to categorize angle closure eyes by disease mechanism. Other ML algorithms that utilize image data have demonstrated good performance in detecting angle closure. Nonetheless, deep learning (DL) algorithms trained directly on image data generally outperformed traditional ML algorithms in detecting PACD, were able to accurately differentiate between angle status (open, narrow, closed), and automated the measurement of quantitative parameters. However, more work is required to expand the capabilities of these AI algorithms and for deployment into real-world practice settings. This includes the need for real-world evaluation, establishing the use case for different algorithms, and evaluating the feasibility of deployment while considering other clinical, economic, social, and policy-related factors.

Authors

  • Zhi Da Soh
    Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
  • Mingrui Tan
    Institute of High Performance Computing, Agency for Science, Technology and Research (A*Star), 1 Fusionopolis Way, 138632, Singapore. Electronic address: tan_mingrui@ihpc.a-star.edu.sg.
  • Monisha Esther Nongpiur
    Singapore Eye Research Institute, Singapore National Eye Centre, 20 College Road, 169856, Singapore; Ophthalmology & Visual Sciences Academic Clinical Programme, Academic Medicine, Duke-NUS Medical School, 8 College Road, 169857, Singapore. Electronic address: monisha.esther.nongpiur@seri.com.sg.
  • Benjamin Yixing Xu
    Roski Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo St #4400, Los Angeles, CA, 90033, USA. Electronic address: benjamix@usc.edu.
  • David Friedman
    Department of Ophthalmology, Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA; Massachusetts Eye and Ear, Mass General Brigham, 243 Charles Street, Boston, MA, 02114, USA. Electronic address: Friedman@MEEI.Harvard.edu.
  • Xiulan Zhang
    Zhongshan Ophthalmic Center, Sun Yat-sen University, China. Electronic address: zhangxl2@mail.sysu.edu.cn.
  • Christopher Leung
    Department of Ophthalmology, School of Clinical Medicine, The University of Hong Kong, Cyberport 4, 100 Cyberport Road, Hong Kong; Department of Ophthalmology, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong Kong. Electronic address: cleung21@hku.hk.
  • Yong Liu
    Department of Critical care medicine, Shenzhen Hospital, Southern Medical University, Guangdong, Shenzhen, China.
  • Victor Koh
    Department of Ophthalmology, National University Hospital, Singapore mgirard@ophthalmic.engineering victor_koh@nuhs.edu.sg.
  • Tin Aung
    Singapore Eye Research Institute, Singapore National Eye Center, Singapore.
  • Ching-Yu Cheng
    Singapore National Eye Centre, Singapore Eye Research Institute, Singapore, Singapore.